Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BK
BKHAR
BK
Black Hawk Acquisition Corporation Rights
BKHAR
News
·
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Mkt Cap
N/A
Volume
22.27K
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Vesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership change comes as Vesicor prepares to complete its proposed de-SPAC merger with Black Hawk Acquisition Corporation and accelerate IND-enabling studies with an FDA submission targeted for 2027.
GlobeNewswire Inc. · Mar 19, 2026
Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, has entered into a business combination agreement with Black Hawk Acquisition Corporation to create a public company advancing its drug candidate.
Benzinga · Apr 28, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BK
BKHAR
Black Hawk Acquisition Corporation Rights
Buy
Sell
Market
Limit
Soon
BKHAR
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BKHAR yet.
Related Tickers
Earnings